A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer

Autor: Cristea, Mihaela C., Stewart, Daphne, Synold, Timothy, Ruel, Nora, Mortimer, Joanne, Wang, Edward, Jung, Alexander, Wilczynski, Sharon, Konecny, Gottfried E., Eng, Melissa, Kilpatrick, Lindsay, Han, Ernest, Dellinger, Thanh, Hakim, Amy, Lee, Stephen, Morgan, Robert J., Wakabayashi, Mark T., Frankel, Paul H.
Zdroj: In Gynecologic Oncology March 2024 182:124-131
Databáze: ScienceDirect
Externí odkaz: